Clinical Trial Update: An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease [Phase 2]

View source ↗

Summary

The open-label extension study of XPro1595 in Alzheimer's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• XPro1595 (XPro1595)

Snippet

Sponsor: Inmune Bio, Inc. | Conditions: Alzheimer Disease, Dementia | Phase 2 | Status: TERMINATED